Delving into the Latest Updates on Modified autologous adipose-derived stem cells (Beijing Jiyuan) with Synapse

Overview

Basic Info

Drug Type

Mesenchymal stem cell therapy

Synonyms-

Target

FGF21

Action

modulators

Mechanism

FGF21 modulators(Fibroblast growth factor 21 modulators)

Therapeutic Areas

Endocrinology and Metabolic Disease

Active Indication

Diabetes Mellitus, Type 2

Inactive Indication-

Originator Organization

Beijing Jiyuan Biotechnology Co., Ltd.

Active Organization

Beijing Jiyuan Biotechnology Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

SAD Main purpose To evaluate the safety and tolerability of single-dose injection of adipose-derived stem cells with high expression of GLP-1 and FGF21 in patients with type 2 diabetes. MAD Main purpose To evaluate the safety and tolerability of multiple-dose injection of adipose-derived stem cells with high expression of GLP-1 and FGF21 in patients with type 2 diabetes.

Start Date23 Sep 2025

Sponsor / Collaborator

Beijing Jiyuan Biotechnology Co., Ltd.

100 Clinical Results associated with Modified autologous adipose-derived stem cells (Beijing Jiyuan)

Login to view more data

100 Translational Medicine associated with Modified autologous adipose-derived stem cells (Beijing Jiyuan)

Login to view more data

100 Patents (Medical) associated with Modified autologous adipose-derived stem cells (Beijing Jiyuan)

Login to view more data

100 Deals associated with Modified autologous adipose-derived stem cells (Beijing Jiyuan)

Login to view more data